Trials / Completed
CompletedNCT03029455
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation, and Bioavailability Study Evaluating the Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Subjects With Cystic Fibrosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 163 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Evaluate the safety and tolerability of VX-659 in healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-659 | |
| DRUG | Tezacaftor | |
| DRUG | Ivacaftor | |
| DRUG | VX-659 Matching Placebo | |
| DRUG | Triple Combination (TC) Matching Placebos |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2017-08-01
- Completion
- 2017-08-01
- First posted
- 2017-01-24
- Last updated
- 2017-09-05
Locations
10 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03029455. Inclusion in this directory is not an endorsement.